Plasma filter sorbent system for removal of components from blood

• US 5,211,850 A
• Filed: 07/26/1991
• Issued: 05/18/1993
• Est. Priority Date: 07/26/1991
• Status: Expired due to Term

• Current Assignee: Jostra Bentley, Inc.
• Original Assignee: Research Medical, Inc. (Baxter International Inc.)
• Inventors: Shettigar, Udipi, McRea, James C.
• Primary Examiner(s): Dawson, Robert A.
• Assistant Examiner(s): KIM, SUN U
• Application Number:
  US07/736,405
• Time in Patent Office: 662 Days
• Field of Search: 210/632, 210/637, 210/645, 210/646, 210/650, 210/484, 210/651, 210/483, 210/653, 210/443, 210/654, 210/444, 210/806, 210/257.2, 210/321.82, 210/321.83 , 210/321.84, 210/321.85, 210/321.86, 210/321.87, 210/321.88, 210/321.89, 210/500.23, 210/502.1, 210/321.8, 210/321.81, 210/195.2, 604/4, 604/5, 604/6, 435/287, 435/288, 436/178, 436/177, 436/519, 436/529, 436/535
• US Class Current: 210/645
• CPC Class Codes: A61M 1/3472 with treatment of the filtrate
• CPC Class Codes: A61M 1/3475 with filtrate treatment agent in the same enclosure as the membrane
• CPC Class Codes: A61M 1/3486 Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
• CPC Class Codes: B01D 2313/40 Adsorbents within the flow path
• CPC Class Codes: B01D 2315/06 Submerged-type; Immersion type
• CPC Class Codes: B01D 61/145 Ultrafiltration
• CPC Class Codes: B01D 63/02 Hollow fibre modules
• CPC Class Codes: B01D 63/024 with a single potted end
• CPC Class Codes: B01D 63/0241 being U-shaped
• CPC Class Codes: Y10T 436/255 including use of a solid sorbent, semipermeable membrane, or liquid extraction

Abstract

A system and method of achieving both convective and diffusive transport of plasma across a membrane accompanied by the selective removal of plasma components using sorbents followed by reinfusion of the purified plasma in a blood circulation system is achieved by pumping blood through a filter comprising a bundle of "U" shaped hollow fibers immersed in a closed plasma chamber containing sorbents in an electrolyte solution. As blood flows through the entry arm, due to positive transmembrane pressure difference, plasma filtration into the plasma chamber occurs. The entering plasma causes an increase in the chamber pressure but does not exceed the pressure in the entry arm. The increase in chamber pressure exceeds the pressure in the exit arm of filter where the transmembrane pressure difference is negative and the direction of filtration reverses causing reverse filtration/reinfusion of plasma from the chamber into the blood in the exit arm. The phenomena of positive and reverse filtration from the hollow fiber filter establishes the circulation of plasma fluid in the plasma chamber. The plasma filtering through the entry arm, which corresponds to the arterial end of the system, passes through the plasma chamber solution containing the sorbents where plasma components get selectively depleted. The sorbents may be in any usable form which are not permeable to the filter. The purified plasma reenters the filter along the exit arm corresponding to the venous end where negative transmembrane pressure exists.

Claims

1. A blood circulation and filtration system for the selective removal of targeted plasma components from blood by means of convective and diffusive transport of plasma from said blood across a filter membrane into a plasma chamber solution where the selective removal of targeted plasma components from non-targeted plasma components using sorbents in the plasma chamber solution is accomplished followed by the subsequent transport of the non-targeted plasma components across the filter membrane back into the blood which comprises:

(a) a closed plasma chamber filled with an electrolyte plasma chamber solution containing one or more sorbents which have an affinity for and bind said targeted plasma components said closed plasma chamber being configured to freely circulate, equilibrate, mix and interact plasma components with said sorbents in said plasma chamber solution under relatively uniform pressure,

(b) a "U" shaped hollow fiber membrane plasma filter having an inlet arm and an outlet arm immersed in said plasma chamber solution in said closed plasma chamber,

(c) means for securing said inlet arm and outlet arm of said fiber filter in said plasma chamber and losing said chamber to maintain relatively uniform plasma chamber solution pressure,

(d) circulation means for directing said blood into said inlet arm, through said filter and out through said outlet arm.

2. A system according to claim 1 wherein said hollow fiber membrane plasma filter consists of a bundle of parallel hollow fibers.

3. A system according to claim 2 wherein said sorbents are of a size and configuration that said sorbents are not permeable to the filter membrane.

4. A system according to claim 3 wherein the hollow fibers making up said filter membrane are constructed of a blood compatible material having a suitable pore size to allow passage of plasma into the plasma chamber solution while retaining blood cells and platelets from the blood within the hollow fibers.

5. A system according to claim 4 wherein the pore sizes in said membrane range between about 0.01μ

to 1.0μ

.

6. A system according to claim 5 wherein hollow fibers are made from a material selected from the group consisting of polypropylene, cellulose diacetate, polycarbonate, polyvinylchloride, polyvinylalcohol, polymethylmethacrylate, polyethylene and polyethylenevinylalcohol.

7. A system according to claim 5 wherein the hollow fibers making up the filter must have a lumen diameter and overall length to allow appropriate amounts of blood to be directed through the filter for a length of time to allow sufficient amounts of plasma to pass from the inlet arm of the filter into the plasma chamber solution and the non-targeted plasma components to pass back into the outlet arm of the filter.

8. A system according to claim 7 wherein said hollow fibers have inside diameters of between about 150 and 500μ

and wall thicknesses of between about 50 to 400μ

.

9. A system according to claim 8 wherein the internal surface area of said filter membrane is between about 0.1 and 5.0 m².

10. A system according to claim 8 wherein the length of the filter is between about 10 and 100 cm.

11. A system according to claim 10 wherein the sorbent in said plasma chamber is in the form of particles, filaments, strands or sheets.

12. A system according to claim 11 wherein the sorbent is a member selected from the group consisting of enzymes, living tissue, fragments of tissue, cells, and immobilized enzymes or antibodies.

13. A system according to claim 11 wherein the sorbent is in the form of particles and has affinity for heparin.

14. A system according to claim 13 wherein the sorbent is agarose.

15. A system according to claim 14 wherein the sorbent is a poly-L-lysine derivatized agarose.

16. A blood circulation and filtration system for the selective removal of targeted plasma components from blood by means of convective and diffusive transport of plasma from said blood across a sorbent containing filter membrane into a plasma chamber solution where the selective removal of targeted plasma components from non-targeted plasma components using sorbents in said filter membrane is accomplished followed by the subsequent transport of the non-targeted plasma components across the filter membrane back into the blood which comprises:

(a) a closed plasma chamber filled with an electrolyte plasma chamber solution, said closed plasma chamber being configured to freely circulate, equilibrate and interact plasma components in said plasma chamber solution under relatively uniform pressure,

(b) a "U" shaped hollow fiber membrane plasma filter containing one or more sorbents which have an affinity for and bind said targeted plasma components having an inlet arm and an outlet arm immersed in said plasma chamber solution in said closed plasma chamber,

(c) means for securing said inlet arm and outlet arm of said fiber filter in said plasma chamber and closing said chamber to maintain relatively uniform plasma chamber solution pressure,

(d) circulation means for directing said blood into said inlet arm, through said filter and out through said outlet arm.

17. A method for the selective removal of targeted plasma components from blood which comprises

(a) providing a blood circulation and filtration system having (1) a closed plasma chamber filled with an electrolyte plasma chamber solution containing one or more sorbents which have an affinity for and bind said targeted plasma components, (2) a "U" shaped hollow fiber membrane plasma filter having an inlet arm and an outlet arm and immersed in said plasma chamber solution in said closed plasma chamber, (3) means for securing said inlet arm and outlet arm of said fiber filter in said plasma chamber and closing said chamber, (4) circulation means for directing blood into said inlet arm, through said filter and out through said outlet arm;

(b) directing blood by said circulation means from a source into said inlet arm, through said filter and out said exit arm at a volume and velocity which permits the convective and diffusive transport of plasma from said blood across said filter membrane along the inlet arm of said filter into said plasma chamber solution,

(c) causing said plasma in said plasma chamber solution to come into contact with said sorbents where said targeted plasma components are selectively bound to said sorbents; and

(d) causing said non-targeted plasma components to pass by diffusive and convective transport from said plasma chamber solution across the filter membrane back into the blood along the outlet arm of said filter and out of said system.

18. A method according to claim 17 wherein cellular components of the blood do not enter the plasma chamber solution or come into contact with the sorbents and wherein the passage of plasma components through said filter membrane is accomplished by convective and diffusive transport in the absence of extraneous pressure control means.

19. A method according to claim 18 wherein the transmembrane pressure difference of the blood in the entry arm of the filter is greater than pressure in the plasma chamber and wherein the plasma entering the plasma chamber from said inlet arm causes a pressure increase in the plasma chamber which does not exceed the pressure in said entry arm of filter but wherein the increase in pressure in the plasma chamber exceeds the transmembrane pressure in the outlet arm of the filter.

20. A method according to claim 19 wherein the blood source contains heparin which is a targeted plasma component.

21. A method according to claim 20 wherein the sorbent in said plasma chamber has a binding affinity for heparin.

22. A method according to claim 21 wherein the sorbent is agarose.

23. A method according to claim 22 wherein the sorbent is a poly-L-lysine derivatized agarose.